Related Experiment Video

Updated: Jul 5, 2025

In Vivo Tracking of Edema Development and Microvascular Pathology in a Model of Experimental Cerebral Malaria Using Magnetic Resonance Imaging
09:04

In Vivo Tracking of Edema Development and Microvascular Pathology in a Model of Experimental Cerebral Malaria Using Magnetic Resonance Imaging

Published on: June 8, 2017

6.5K

N-(coumarin-3-yl)cinnamamide Promotes Immunomodulatory, Neuroprotective, and Lung Function-Preserving Effects during

Paulo Gaio1, Allysson Cramer1, Natália Fernanda de Melo Oliveira1

  • 1Department of Biochemistry and Immunology, Institute of Biological Science, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.

Pharmaceuticals (Basel, Switzerland)
|January 23, 2024
PubMed

Insights

N-(coumarin-3-yl)cinnamamide (M220) treatment protected cognitive and lung functions in mice with severe malaria. M220 reduced brain and lung inflammation by modulating immune cell activity, suggesting therapeutic potential.

Area of Science:

  • Immunology
  • Neuroscience
  • Pharmacology

Background:

  • * Plasmodium berghei ANKA (PbA) infection in mice serves as a model for severe human malaria, including cerebral malaria and acute respiratory distress syndrome.
  • * Severe malaria is characterized by significant inflammation in the brain and lungs, leading to cognitive and respiratory impairments.

Purpose of the Study:

  • * To investigate the therapeutic effects of N-(coumarin-3-yl)cinnamamide (M220) on severe experimental malaria.
  • * To evaluate M220's impact on cognitive function, lung function, and inflammatory markers in PbA-infected mice.

Main Methods:

  • * Experimental infection of mice with Plasmodium berghei ANKA.
  • * Administration of N-(coumarin-3-yl)cinnamamide (M220) to infected mice.
  • * Assessment of cognitive function using an object recognition test.
  • * Measurement of lung function via spirometry.
  • * Analysis of brain and lung inflammation, including immune cell profiling and cytokine levels (TNF, IFN-γ, IL-10).

Main Results:

  • * M220 treatment significantly protected cognitive abilities and preserved lung function in PbA-infected mice.
  • * Treated mice exhibited reduced brain and lung inflammation.
  • * Decreased production and accumulation of microglia and pro-inflammatory cytokines (TNF, IFN-γ) were observed.
  • * Enhanced production of the anti-inflammatory cytokine IL-10 was noted in treated mice.

Conclusions:

  • * N-(coumarin-3-yl)cinnamamide (M220) demonstrates immunomodulatory, neuroprotective, and lung function-preserving effects in experimental severe malaria.
  • * M220 effectively reduces neuroinflammation and lung inflammation associated with PbA infection.
  • * M220 shows promise as a potential therapeutic candidate for managing severe malaria complications.
Keywords:
N-(coumarin-3-yl)cinnamamidePlasmodium berghei ANKAacute respiratory distress syndromecerebral malariaimmunoregulation

More Related Videos

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine08:31

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

Published on: October 11, 2019

10.3K
Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases09:13

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

1.4K

Related Concept Videos

Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.1K
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
441
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
163
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
279